Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs), including antibodies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein-1 (PD-1), have shown durable treatment responses in multiple tumor types by enhancing antitumor immunity. However, removal of self-tolerance can...

Full description

Saved in:
Bibliographic Details
Published in:BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy biopharmaceuticals, and gene therapy, 2016-12, Vol.30 (6), p.571-584
Main Authors: Day, Daphne, Hansen, Aaron R.
Format: Article
Language:English
Subjects:
Antibodies
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - adverse effects
Antigens
Autoimmune Diseases - etiology
B7-H1 Antigen - immunology
B7-H1 Antigen - metabolism
Biomarkers
Biomarkers - analysis
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Chemoradiotherapy - adverse effects
Clinical trials
Clinical Trials as Topic
CTLA-4 Antigen - immunology
CTLA-4 Antigen - metabolism
Cytokines
Cytotoxicity
Design
Dose-Response Relationship, Drug
Funding
Gene expression
Guillain-Barre syndrome
HIV Infections - etiology
Humans
Immune system
Immune Tolerance - drug effects
Inflammatory bowel disease
Ipilimumab
Medical research
Melanoma
Molecular Medicine
Molecular Targeted Therapy - methods
Patients
Pharmaceutical industry
Pharmacotherapy
Programmed Cell Death 1 Receptor - immunology
Programmed Cell Death 1 Receptor - metabolism
Quality
Regulatory approval
Review Article
Studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors (ICIs), including antibodies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein-1 (PD-1), have shown durable treatment responses in multiple tumor types by enhancing antitumor immunity. However, removal of self-tolerance can induce autoimmunity and produce a unique immune-driven toxicity profile, termed immune-related adverse events (irAEs). As ICIs gain approval for a growing number of indications, it is imperative clinicians increase their knowledge of and ability to manage irAEs. This review examines the etiology, presentation, kinetics, and treatment of irAEs and aims to provide practical guidance for clinicians.
ISSN:1173-8804
1179-190X
DOI:10.1007/s40259-016-0204-3